Riskpilot← Back to searchSign inGet full accessLaurantis Pharma Oy
OYActiveY-tunnus 2210546-0Itäinen Pitkäkatu 4-BMuu luonnontieteellinen ja tekninen tutkimus ja kehitt. · NACE 72190Est. 2008— employeeswww.laurantis.com
Revenue 2021
EUR 0
EBITDA margin
—
+35% vs 2020
Equity ratio
-1084.5%
Financial strength
Net profit 2021
EUR -867K
+35% vs 2020
| Revenue | EUR 0 | — |
| EBITDA | EUR -851K | +35% |
| Net profit | EUR -867K | +35% |
| Total assets | EUR 844K | +15% |
| Equity | EUR -9,1M | -10% |
| Employees | — | — |
Legal name
Laurantis Pharma Oy
Y-tunnus number
2210546-0
Legal form
Osakeyhtiö
NACE code
72190 · Muu luonnontieteellinen ja tekninen tutkimus ja kehitt.
Founded
5. elokuuta 2008
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen ja toimitusjohtaja yhdessä sekä hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimialana on bioteknologiaan ja lääketieteeseen liittyvä tutkimus- ja tuotekehitystoiminta sekä bioteknologiaan ja lääketieteeseen liittyvien tuotteiden ja palvelujen tuotanto, myynti ja markkinointi Suomessa ja ulkomailla. Yhtiö voi omistaa ja hallinnoida kiinteistöjä ja arvopapereita sekä käydä niillä kauppaa. Yhtiö voi harjoittaa toimintaansa suoraan taikka tytär- tai osakkuusyhtiöidensä välityksellä.
Address
Itäinen Pitkäkatu 4-B
Phone
+358408494694
Email
info@laurantis.com
Website
www.laurantis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −847 | −1 536 | −1 314 | −851 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | −848 | −1 537 | −1 314 | −851 |
| Net financials | −165 | −24 | −24 | −16 |
| Profit before tax | −1 012 | −1 561 | −1 338 | −867 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −1 012 | −1 561 | −1 338 | −867 |
| Item | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Total assets | 227 | 524 | 732 | 844 |
| Equity | −5 383 | −6 945 | −8 282 | −9 150 |
| Long-term debt | 5 096 | 7 414 | 8 675 | 9 275 |
| Short-term debt | 515 | 54 | 339 | 719 |
| Total debt | 5 610 | 7 468 | 9 014 | 9 993 |
EBITDA margin
-85102500.0%
This company
15.8%
Market median
-538623518% vs market
20182021
Equity ratio
-1084.5%
This company
38.2%
Market median
-2939% vs market
20182021
Return on equity
-86705000.0%
This company
18.4%
Market median
-471222926% vs market
20182021
Net profit margin
-86705000.0%
This company
8.1%
Market median
-1070432199% vs market
20182021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182021
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20182021
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via PRH / YTJ · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AT Person with significant control | Person with significant control | 2022 |
| Former (5) | ||
CR Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
PI Chief Executive Officer | Chief Executive Officer | 2014 – 2020 |
BB Person with significant control | Person with significant control | 2015 – 2022 |
FG Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
MA | Audit | 2015 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2014 – 2020 | |
| Board of Directors | 2014 – 2022 | |
| Chairperson | 2014 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Laurantis Pharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Craig Richard Cook | Chief Executive Officer | 0 companies |
| Pekka Ilmari Simula | Chief Executive Officer | 0 companies |
| Burkhard Blank | Person with significant control | 0 companies |
| Antti Tapani Vuolanto | Person with significant control | 0 companies |
| Frans Gustaf Wuite | Chief Executive Officer | 0 companies |
| Martin Andreas Grandell | Audit | 0 companies |
| Timo Ilari Veromaa | Board of Directors | 0 companies |
| Aki Pellervo Prihti | Board of Directors | 0 companies |
| Pekka Allan Antero Mattila | Chairperson | 0 companies |